🎨Science Visuals | 🎯Targeted therapies are transforming treatment for #ColorectalCancer (#CRC)
🔸Key approaches include #EGFR inhibitors like #Cetuximab & #Panitumumab and #VEGF inhibition with #Bevacizumab.
🚫#Tumor growth and #angiogenesis.
#Cancer #CancerResearch #Oncology

FDA Greenlights Amgen’s Dual Therapy for KRAS G12C-Mutated Colorectal Cancer On January 16, 2025, the U.S.

www.linkedin.com/pulse/fda-gr...

FDA Greenlights Amgen’s Dual Therapy for KRAS G12C-Mutated Colorectal Cancer

kstrategyand.com/pharma-news

#FDAApproval #Amgen #Sotorasib #Panitumumab #ColorectalCancer #KRASG12C #CancerCare #HealthBreakthrough #Humanteconomy #Humantec #KStrategyand

Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social

👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor re…

A-REPEAT trial: #panitumumab based #rechallenge strategy in pretteated metastatic #crc pts. The study was closed prematurely but highlights the importance of #LiquidBiopsy before rechallenge:48% of pts were RAS mutant #GIonc #OncSky @christianrolfo.bsky.social www.sciencedirect.com/science/arti...

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Cli... PURPOSETo investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the...

TTO intermitente c/fluorouracilo, leucovorina e irinotecán +panitumumab luego de inducción en pac c/CA colorrectal MT salvaje RAS/BRAF irresecable, mejora supervivencia libre de progresión en TTO c/menos toxicidad #FOLFIRI #panitumumab #mCRC ascopubs.org/doi/full/10....

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRA...

#MedSky🧪
KRAS G12C is a mutation that occurs in approx 3 - 4% of metastatic #colorectalcancer. Tx with #sotorasib at a dose of either 960 mg or 240 mg, in combination with #panitumumab, resulted in significantly longer progression-free survival than standard-care Tx.

www.nejm.org/doi/full/10....